About this trial
A phase II, single-center, non-profit, interventional study on patients affected by rectal adenocarcinoma. Patients will be stratified into three groups based on pre-treatment clinical stage. The study investigates and may propose a comprehensive, stage-specific, multimodal approach to rectal adenocarcinoma, with a focus on organ preservation even in early stages (cT1-2N0). When organ-sparing strategies are not feasible, the approach prioritizes minimally invasive techniques (laparoscopic and robotic) to reduce the physical, psychological, and quality-of-life impact on patients.
Eligibility criteria
Qualifiers
Patients aged ≥18 yrs old
Patients able to sign the informed consent
Patients with High Risk pT1 rectal adenocarcinoma endoscopically excised
Patients with cT2-3aN0 rectal adenocarcinoma who has complete/major response to EXPERIMENTAL CRT
Disqualifiers
cT2-4 any NM0 who don't reach cCR or cMR after experimental/standard CRT
Pregnancy
Trial design
Treatments tested in this trial
- Sparing Approach
- experimental chemoradiotherapy
- Standard Chemotherapy